Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Neuroendocrine
Status:
Closed
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
EA21452 is closed to accrual effective April 1, 2021.
NCT#02595424
